Skip to main content Accessibility help
×
Home

Noradrenergic Pathology in Psychiatric Disorders: Postmortem Studies

  • Gregory A. Ordway and Violetta Klimek

Abstract

In this paper, we review research utilizing postmortem brain tissue in order to investigate the potential neuropathology of the noradrenergic system in psychiatri disorders. The postmortem tissue approach to the study of the noradrenergic system has been used primarily in investigations of the biology of suicide and depression. Findings from postmortem studies provide data generally consisten with the hypothesis that a norepinephrine deficiency exist depression, and possibly in the victims of suicide. However postmortem studies do not presently provide irrefutable evidence of noradrenergic neuropathology. Technical shortcomings, issues of reproducibility, and the strengths postmortem research are reviewed. More rigorously performed postmortem research is needed to aid researchers in pinpointing specific neuropathologies associated with psychiatric disease.

Copyright

Corresponding author

Please direct correspondence to: Gregory A. Ordway, PhD, Professor and Director, Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216. Tel: 601-984-5893; Fax: 601-984-5894; E-mail: gordway@psychiatry.umsmed.edu.

References

Hide All
1. Prange, AJ Jr., The pharmacology and biochemistry of depression. Dis New Syst. 1964;5:217221.
2. Schildkraut, JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509522.
3. Koslow, SH, Maas, JW, Bowden, CL et al. , CSF and urinary biogenic amines and metabolites in depression and mania: a controlled, univariate analysis. Arch Gen Psychiatry. 1983;40:9991010.
4. Redmond, DE, Katz, MM, Maas, JW et al. , Cerebrospinal fluid amine metabolites: relationships with behavioral measurements in depressed, manic, and healthy control subjects. Arch Gen Psychiatry. 1986;43:938947.
5. Beckmann, H, Goodwin, FK. Urinary MHPG in subgroups of depressed patients and normal controls. Neuropsychobiology. 1980;6:91100.
6. Roy, A, Pickar, D, Linnoila, M, Potter, WZ. Plasma norepinephrine level in affective disorders: relationship to melancholia. Arch Gen Psychiatry. 1985;42:11811185.
7. Veith, R, Lewis, N, Linares, O et al. , Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry. 1994;51:411422.
8. Charney, DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59(Suppl 14):1114.
9. Salomon, R, Miller, HL, Krystal, JH et al. , Lack of behavioral effects of monoamine depletion in healthy subjects. Biol Psychiatry. 1997;41:5864.
10. Delgado, PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61(Suppl 6):711.
11. Berman, RM, Narasimhan, M, Miller, H et al. , Transient depressive relapse induced by catecholamine depletion. Arch Gen Psychiatry. 1999;56:395403.
12. Hornykiewicz, O. Brain noradrenaline and schizophrenia. In: JM, Van Ree, SW, Matthysse, eds. Progress in Brain Research. Vienna: Elsevier Science Publisher; 1986:2939.
13. Weinberger, DR. Schizophrenia and the frontal lobe. TINS. 1988;11:367370.
14. Archer, T, Ogren, SO, Johansson, G, Ross, SB. DSP4-induced two-way active avoidance impairment in rats: involvement of central and not peripheral noradrenaline depletion. Psychopharmacology. 1982;76:303309.
15. Mason, ST. Noradrenaline in the brain: progress in theories of behavioural function. Prog Neurobiol. 1981;16:263303.
16. Plaznik, A, Pucilowski, O, Kostowski, W et al. , Rotational behavior produced by unilateral ventral noradrenergic bundle lesions: evidence for a noradrenergic-dopaminergic interaction in the brain. Pharmacol Biochem Behav. 1982;17:619622.
17. Lake, CR, Steinberg, DE, van Kammen, DP et al. , Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science. 1980;207:331333.
18. Sternberg, DE, Van Kammen, DP, Lake, CR et al. , The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry. 1981;138:10451050.
19. Van Kammen, DP, Antelman, S. Impaired noradrenergic transmission in schizophrenia? [Review]. Life Sci. 1984;34:14031413.
20. Rich, CL, Young, D, Fowler, RC. San Diego suicide study. Arch Gen Psychiatry. 1986;43:577582.
21. Stockmeier, CA, Jurjus, G. Monoamine receptors in postmortem brain tissue in suicide. In: Agam, G, RH, Belmaker, Everall, I, eds. The Postmortem Brain in Psychiatric Research. Kluwer Academic Publishers; Dortrecht, the Netherlands; 2001: in press.
22. De Paermentier, F, Mauger, JM, Lowther, S et al. , Brain alpha-adrenoceptors in depressed suicides. Brain Res. 1997;757:6068.
23. Arango, V, Ernsberger, P, Syed, AF, Mann, JJ. Quantitative autoradiography of a1 and a2 adrenergic receptors in the cerebral cortex of controls and suicide vietims. Brain Res. 1993;630:271282.
24. Gross-Isseroff, R, Dillon, KA, Fieldust, SJ, Biegon, A. Autoradiographic analysis of alpha 1-noradrenergic receptors in the human brain postmortem. Effect of suicide [published erratum appears in Arch Gen Psychiatry 1991 Sep;48(9):862]. Arch Gen Psychiatry: 1990;47:10491053.
25. Crow, TJ, Cross, AJ, Cooper, SJ et al. , Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology. 1984;23:15611569.
26. Klimek, V, Rajkowska, G, Luker, SN et al. , Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology. 1999;21:6981.
27. Ferrier, IN, McKeith, IG, Cross, AJ et al. , Postmortem neurochemical studies in depression. Ann N Y Acad Sci. 1986;487:128142.
28. Meana, JJ, Garcia-Sevilla, JA. Increased a2-adrenoceptor density in the frontal cortex of depressed suicide victims. J Neural Transm. 1987;70:377381.
29. Meana, JJ, Barturen, F, Garcia-Sevilla, JA. Alpha2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry. 1992;31:471490.
30. Sirota, P. Is schizophrenia an autoimmune disease. Isr J Med Sci. 1990;26:694697.
31. Joyce, JN, Lexow, N, Jin Kim, S et al. , Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: Alterations in limbic regions of schizophrenics. Synapse. 1992;10:228246.
32. Bennett, JP, Enna, SJ, Bylund, DB et al. , Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry. 1979;36:927934.
33. De Paermentier, F, Cheetham, SC, Crompton, MR et al. , Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res. 1990;525:7177.
34. Mann, JJ, Stanley, M, McBride, PA, McEwen, BS. Increased serotonin2 and b-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry. 1986;43:954959.
35. Arango, V, Ernsberger, P, Marzuk, PM et al. , Autoradiographic demonstration of increased serotonin 5-HT2 and B-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry. 1990;47:10381047.
36. Biegon, A, Israeli, M. Regionally selective increases in b-adrenergic receptor density in the brains of suicide victims. Brain Res. 1988;442:199203.
37. Gross-Isseroff, R, Israeli, M, Biegon, A. Autoradiographic analysis of [3H] desmethylimipramine binding in the human brain postmortem. Brain Res. 1988;456:120126.
38. Arora, RC, Meltzer, HY. Laterality and 3H-imipramine binding: studies in the frontal cortex of normal controls and suicide victims. Biol Psychiatry. 1991;29:10161022.
39. Stanley, M, Virgilio, J, Gershon, S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science. 1982;216:13371339.
40. Grote, SS, Moses, SG, Robins, E et al. , A study of selected catecholamine metabolizing enzymes: a comparison of depressive suicides and alcoholic suicides with controls. J Neurochem. 1974;23:791802.
41. Mann, J. J. and Stanley, M.postmortem monoamine oxidase enzyme kinetics in the frontal cortex of suicide victims and controls. Acta Psychiatr Scand. 1984;69:135139.
42. Maeztu, AI, Ballesteros, J, Callado, LF et al. , The density of monoamine oxidase B sites is not altered in the postmortem brain of alcoholics. Alcohol Clin Exp Res. 1997;21:14791483.
43. Gottfries, CG, Oreland, L, Wiberg, A, Winblad, B. Lowered monoamine oxidase activity in brains from alcoholic suicides. J Neurochem. 1975;25:667673.
44. Callado, LF, Meana, JJ, Grijalba, B et al. , Selective increase of a2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem. 1998;70:11141123.
45. Garcia, S, Escriba, PV, Ozaita, A et al. , Up-regulation of immunolabeled alpha2Aadrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem. 1999;72:282291.
46. Ordway, GA, Widdowson, PS, Smith, KS, Halaris, A. Agonist binding to a2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J Neurochem. 1994;63:617624.
47. Ordway, GA, Schenck, JE, Dilley, GE et al. , Increased p-[125I]iodoclonidine binding to a2-adrenoceptors in the locus coeruleus in major depression. Soc Neurosci Abs. 1999;25:2139
48. Klimek, V, Stockmeier, CA, Overholser, JC et al. , Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 1997;17:84518458.
49. Ordway, GA, Farley, IJ, Dilley, GE et al. , Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Res. 1999;847:7179.
50. Ordway, GA, Smith, KS, Haycock, JW. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J Neurochem. 1994;62:680685.
51. Zhu, M-Y, Klimek, V, Dilley, GE et al. , Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry. 1999;46:12751286.
52. Biegon, A, Fieldust, S. Reduced tyrosine hydroxylase immunoreactivity in locus coeruleus of suicide victims. Synapse. 1992;10:7982.
53. Baumann, B, Danos, P, Diekmann, S et al. , Tyrosine hydroxylase immunoreactivity in the locus coeruleus is reduced in depressed non-suicidal patients but normal in depressed suicide patients. Eur Arch Psychiatry Clin Neurosci. 1999;249:212219.
54. Arango, V, Undenvood, MD, Mann, JJ. Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results. Biol Psychiatry. 1996;39:112120.
55. Danysz, W, Kostowski, W, Hauptmann, M. Evidence for the locus coeruleus involvement in desipramine action in animal models of depression. Pol J Pharmacol Pharm. 1985;7:855864.
56. Wolfe, BB, Harden, TK, Sporn, JR, Molinoff, PB. Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther. 1978;207:446457.
57. Biegon, A, Rainbow, TC. Localization and characterization of [3H]desmethylimipramine binding sites in rat brain by quantitative autoradiography. J Neurosci. 1983;3:10691076.
58. Richards, JG, Saura, J, Ulrich, J, DaPrada, M. Molecular neuroanatomy of monoamine oxidases in human brainstem. Psychopharmacology. 1992;106 (Suppl):S2123.
59. Cortes, R, Soriano, E, Pazos, A et al. , Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Neuroscience. 1988;27:473496.
60. Hrdina, PD, Foy, B, Hepner, A, Summers, RJ. Antidepressant binding sites in the brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. J Pharmacol Exp Ther. 1990;52:410418.
61. Kovachich, GB, Frazer, A, Aronson, CE. Effect of chronic administration of antidepressants on alpha 2-adrenoceptors in the locus coeruleus and its projection fields in rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 1993;8:5765.
62. Melia, KR, Rasmussen, K, Terwilliger, RZ et al. , Coordinate regulation of the cyclic AMP system with firing rate and expression of tyrosine hydroxylase in the rat locus coeruleus: effects of chronic stress and drug treatments. J Neurochem. 1992;58:494502.
63. Weiss, JM, Goodman, PA, Losito, BG et al. , Behavioral depression produced by an uncontrollable stressor: Relationship to norepinephrine, dopamine, and serotonin levels in various regions of rat brain. Brain Res Rev. 1981;3:167205.
64. U'Prichard, DC, Bechtel, WD, Rouot, BM, Snyder, SH. Multiple apparent alphanoradrenergic receptor binding sites in rat brain: effect of 6-hydroxydopamine. Mol Pharmacol. 1979;16:4760.
65. Gross, G, Gothert, M, Glapa, U et al. , Lesioning of serotoninergic and noradrenergic nerve fiber's of the rat brain does not decrease binding of 3H-clonidine and 3H-rauwolscine to cortical membranes. Naunyn-Schmiedeherg's Arch Pharmacol. 1985;328:229235.
66. Cubells, JF, Kim, KS, Baker, H et al. , Differential in vivo regulation of mRNA encoding the norepinephrine transporter and tyrosine hydroxylase in rat adrenal medulla and locus coeruleus. J Neurochem. 1995;65:502509.
67. Lee, C-M, Javitch, JA, Snyder, SH. Recognition sites for norepinephrine uptake: regulation by neurotransmitter. Science. 1983;220:626629.
68. Johnson, EW, Wolfe, BB, Molinoff, PB. Regulation of subtypes of B-adrenergic receptors in rat brain following treatment with 6-hydroxydopamine. J Neurosci. 1989;9:22972305.
69. Ordway, GA, Gambarana, C, Frazer, A. Quantitative autoradiography of central beta adrenoceptor subtypes: comparison of the effects of chronic treatment with desipramine or centrally administered l-isoproterenol. J Pharmacol Exp Ther. 1988;247:379389.
70. Ordway, GA, Klimek, V, Mann, JJ. Neurocircuitry of mood disorders. In: Anonymous Psychopharmacology: The Fifth Generation of Progress. 2001: in press.

Related content

Powered by UNSILO

Noradrenergic Pathology in Psychiatric Disorders: Postmortem Studies

  • Gregory A. Ordway and Violetta Klimek

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.